Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6002 + SG001 in advanced urothelial carcinoma and other advanced solid tumors
CTR20242432Phase 2Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Aug 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CRB-701, PBI-1308 in transitional cell carcinoma (TCC), Nonhematologic neoplasms, sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Aug 2024; status: active.
02
Drugs
CRB-701PBI-1308
03
Conditions
transitional cell carcinoma (TCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20242432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242432.